KWALITY PHARMACEUTICALS
|
|
BOM : 539997     NSE :      | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward Pledged Shares : NA |
Feb 14,2025 |
Price(EOD): ₹ 755.45
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 785.67 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
KWALITY PHARMACEUTICALS | -3.1% | -16.6% | 68.5% |
SUN PHARMACEUTICAL INDUSTRIES | -0.2% | -1% | 9.8% |
CIPLA | -0% | 2% | -0.5% |
DR REDDYS LABORATORIES | -1.4% | -6.1% | -4% |
ZYDUS LIFESCIENCES | -5.2% | -4.7% | 8.9% |
DIVIS LABORATORIES | -2.1% | 1.5% | 61.3% |
MANKIND PHARMA | -0.8% | -2% | 11.2% |
TORRENT PHARMACEUTICALS | -5.7% | -3.3% | 16.8% |
LUPIN | -6.5% | -2.1% | 25.9% |
FUNDAMENTAL ANALYSIS OF KWALITY PHARMACEUTICALS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF KWALITY PHARMACEUTICALS
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
26.52
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 29.56 Cr
[Latest Qtr - Dec2024 - Consolidated Results ] 3.5
P/B Calculated based on Book Value of Rs 224.21 Cr
[Latest Year - Mar2024 - Consolidated Results ] 2.26
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 346.50 Cr
[Latest Qtr - Dec2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
197% 849% 415% |
SHARE PRICE MOMENTUM OF KWALITY PHARMACEUTICALS
KWALITY PHARMACEUTICALS vs SENSEX
DEBT OF KWALITY PHARMACEUTICALS
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.44 0.45 0.3 0.4 |
0.44 0.45 0.3 0.4 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF KWALITY PHARMACEUTICALS
Pledged Promoter Shares |
NA | |
---|---|---|
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF KWALITY PHARMACEUTICALS
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-6.25% -11.01% -9.25% 0.78% |
8.08% 4.85% 16.85% 10.98% |
QtrlyTrend |
2 | |
Latest Qtr: Dec2024 | ||
Quarterly Result Analysis → |
KWALITY PHARMACEUTICALS related INDICES
You may also like the below Video Courses
FAQ about KWALITY PHARMACEUTICALS
Is KWALITY PHARMACEUTICALS good for long term investment?
As on Feb 14,2025, the Fundamentals of KWALITY PHARMACEUTICALS look Strong and hence it may be good for long term investment! See Financial Performance of KWALITY PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is KWALITY PHARMACEUTICALS UnderValued or OverValued?
As on Feb 14,2025, KWALITY PHARMACEUTICALS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of KWALITY PHARMACEUTICALS ?
As on Feb 14,2025, the Intrinsic Value of KWALITY PHARMACEUTICALS is Rs. 146.81 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 254.14
Fair Value [Median EV / Sales Model] : Rs. 79.61
Fair Value [Median Price / Sales Model] : Rs. 146.81
Estimated Median Fair Value of KWALITY PHARMACEUTICALS : Rs. 146.81
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.